Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DEVICE

Intradermal insulin delivery: BD Research Catheter Set

1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)

DEVICE

Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set

1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)

Trial Locations (1)

D-41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

Sponsors
All Listed Sponsors
lead

Becton, Dickinson and Company

INDUSTRY